Endocrinology

UArizona Steele Children's Research Center pediatric endocrinologists are focused on exploring ways to better understand and treat hormone conditions affecting children.

Newly diagnosed with Type 1 Diabetes, contact the Steele Children's Research Center office for a Diabetes Kit full of helpful items. 520-626-1614

 

Current Clinical Studies 



Type 1 Diabetes Mellitus


TrialNet 

TrialNet is an international network dedicated to the study, prevention, and early treatment of Type 1 Diabetes (T1D). TrialNet sites are located throughout the United States and internationally, including here at the University of Arizona.
 

Pathway to Prevention (P2P)

The goal of the TrialNet Pathway to Prevention is to enhance our understanding of the demographic, immunologic, and metabolic characteristics of individuals at risk for developing Type 1 Diabetes. The P2P Study tests for antibodies associated with T1D in the blood.

A positive antibody test is an early sign that damage to insulin-secreting cells may have begun. Individuals with antibodies are offered the opportunity for further testing to determine their risk of developing T1D and to monitor for the condition. These results will also be used to identify people eligible to enroll in prevention and intervention studies.


FREADOM: Family Routines Enhancing Adolescent Diabetes by Optimizing Management 


Principal Investigator:  Michelle Perfect, PhD - mperfect@arizona.edu
Enrollment: Open. Type 1 Diabetes, ages 10-17.
 
This study is a collaboration with researchers in the College of Education. The purpose of the study is to look at how assisting families in their daily routines affects diabetes management.
 

T1D Webinar 

 

 

Type 2 Diabetes Mellitus
 

DINAMO: Diabetes study of linagliptin and empagliflozin in children and adolescents 


Principal Investigator:  Mark Wheeler, MD
Enrollment: Open. Type 2 Diabetes ≥ 8 weeks, ages 10-17.
 
This industry-sponsored clinical study is examining how well two different drugs taken by mouth work in adolescents with Type 2 diabetes (T2D). They are already approved for adults with T2D.